CCCC
What one share of C4 Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation, or TPD, science to create a new generation of small-molecule medicines that transform patients’ lives.
C4 Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.31 |
|---|---|
| Profit | −$0.91 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.76 |
| Cash and investments | $0.64 |
| Book value | $2.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$31.03 | $0.98 | $39.55 | — | −$78.48 |
| 2020 | — | −$5.83 | $0.06 | −$5.97 | — | — |
| 2021 | $0.99 | −$1.82 | $0.03 | −$1.92 | — | $8.00 |
| 2022 | $0.64 | −$2.62 | $0.11 | −$2.28 | — | $5.91 |
| 2023 | $0.42 | −$2.67 | $0.03 | −$2.19 | — | $4.07 |
| 2024 | $0.51 | −$1.52 | $0.00 | −$0.94 | — | $3.06 |
| 2025 | $0.43 | −$1.27 | $0.01 | −$1.20 | — | $2.65 |